BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 21081574)

  • 41. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology?
    Basu S; Mavi A; Cermik T; Houseni M; Alavi A
    Mol Imaging Biol; 2008; 10(1):62-6. PubMed ID: 18000713
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PET/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases.
    Davidson T; Shehade N; Nissan E; Sklair-Levy M; Ben-Haim S; Barshack I; Zippel D; Halevy A; Chikman B
    Surg Oncol; 2021 Sep; 38():101567. PubMed ID: 33866190
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study.
    Pritchard KI; Julian JA; Holloway CM; McCready D; Gulenchyn KY; George R; Hodgson N; Lovrics P; Perera F; Elavathil L; O'Malley FP; Down N; Bodurtha A; Shelley W; Levine MN
    J Clin Oncol; 2012 Apr; 30(12):1274-9. PubMed ID: 22393089
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Implication of ¹⁸F-Fluorodeoxyglucose Uptake of Affected Axillary Lymph Nodes in Cases with Breast Cancer.
    Fujii T; Yajima R; Tatsuki H; Oosone K; Kuwano H
    Anticancer Res; 2016 Jan; 36(1):393-7. PubMed ID: 26722071
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Positron emission tomography-computed tomography in the detection of axillary lymph node metastasis in patients with early stage breast cancer.
    Chae BJ; Bae JS; Kang BJ; Kim SH; Jung SS; Song BJ
    Jpn J Clin Oncol; 2009 May; 39(5):284-9. PubMed ID: 19318373
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prediction of Advanced Axillary Lymph Node Metastases (ypN2-3) Using Breast MR imaging and PET/CT after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma Patients.
    Kim WH; Lee SW; Kim HJ; Chae YS; Jeong SY; Jung JH; Park HY; Lee WK
    Sci Rep; 2018 Feb; 8(1):3181. PubMed ID: 29453385
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
    Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L
    Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy.
    Fehr MK; Hornung R; Varga Z; Burger D; Hess T; Haller U; Fink D; von Schulthess GK; Steinert HC
    Breast J; 2004; 10(2):89-93. PubMed ID: 15009033
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients.
    Straver ME; Aukema TS; Olmos RA; Rutgers EJ; Gilhuijs KG; Schot ME; Vogel WV; Peeters MJ
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1069-76. PubMed ID: 20130860
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Subtype-Guided
    Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
    Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of Dual-Timepoint
    Collarino A; Garganese G; Valdés Olmos RA; Stefanelli A; Perotti G; Mirk P; Fragomeni SM; Ieria FP; Scambia G; Giordano A; Rufini V
    J Nucl Med; 2017 Dec; 58(12):1913-1918. PubMed ID: 28546331
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic performance of
    Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
    Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnostic and prognostic value of (18)F-FDG PET/CT for axillary lymph node staging in patients with breast cancer.
    Kitajima K; Fukushima K; Miyoshi Y; Katsuura T; Igarashi Y; Kawanaka Y; Mouri M; Maruyama K; Yamano T; Doi H; Yamakado K; Hirota S; Hirota S
    Jpn J Radiol; 2016 Mar; 34(3):220-8. PubMed ID: 26715510
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The roles of
    Nakano Y; Noguchi M; Yokoi-Noguchi M; Ohno Y; Morioka E; Kosaka T; Takahashi T; Minato H
    Breast Cancer; 2017 Jan; 24(1):121-127. PubMed ID: 27015862
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
    Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
    J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection of internal mammary lymph node metastasis with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer.
    Seo MJ; Lee JJ; Kim HO; Chae SY; Park SH; Ryu JS; Ahn SH; Lee JW; Son BH; Gong GY; Moon DH
    Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):438-45. PubMed ID: 24196918
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prediction of the axillary lymph-node metastatic burden of breast cancer by
    Li Y; Han D; Shen C
    BMC Cancer; 2024 Jun; 24(1):704. PubMed ID: 38849770
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and ¹⁸F-FDG PET/CT.
    You S; Kang DK; Jung YS; An YS; Jeon GS; Kim TH
    Br J Radiol; 2015 Aug; 88(1052):20150143. PubMed ID: 26110204
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure.
    van der Noordaa MEM; van Duijnhoven FH; Straver ME; Groen EJ; Stokkel M; Loo CE; Elkhuizen PHM; Russell NS; Vrancken Peeters MTFD
    Ann Surg Oncol; 2018 Jun; 25(6):1512-1520. PubMed ID: 29511992
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    Wu J; Tian J; Zhang Y; Ji H; Sun J; Wang X; Sun C; Wang L; Teng Z; Lu G; Zhu H; Chen X
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2869-2876. PubMed ID: 35138445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.